Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights

Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Neovascular Age-Related Macular Degeneration (nAMD) Overview

Neovascular age-related macular degeneration (nAMD) is an advanced, exudative variant of macular degeneration characterized by choroidal neovascularization, where pathological vessels sprout from the choriocapillaris into the subretinal space. Driven by vascular endothelial growth factor (VEGF) upregulation, these leaky vessels cause subretinal hemorrhage, macular fluid accumulation, and pigment epithelial detachment, leading to rapid, irreversible central vision loss. Diagnosis relies on optical coherence tomography displaying intraretinal or subretinal fluid, alongside fluorescein angiography to map neovascular architecture. In 2026, standard management centers on proactive, personalized treat-and-extend intravitreal anti-VEGF injection protocols. While traditional mono-targeted agents like aflibercept 2mg or biosimilars remain foundational, frontline regimens preferentially deploy longer-acting, next-generation therapeutics to minimize real-world treatment burden. These include faricimab, a bispecific antibody dual-targeting VEGF-A and angiopoietin-2 to optimize vascular stability, and high-dose aflibercept 8mg, which utilizes structural pharmacokinetic intensification to safely extend standard maintenance dosing intervals up to sixteen weeks. Early detection, strict compliance tracking, and lifestyle optimization are mandatory to preserve long-term functional autonomy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
  • Global findings
  • G8 findings
  • Regional findings
  • Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)